Literature DB >> 23024162

Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases.

Nelson Leung1, Morie Gertz, Robert A Kyle, Fernando C Fervenza, Maria V Irazabal, Alfonso Eirin, Shaji Kumar, Stephen S Cha, S Vincent Rajkumar, Martha Q Lacy, Steve R Zeldenrust, Francis K Buadi, Suzanne R Hayman, Samih H Nasr, Sanjeev Sethi, Marina Ramirez-Alvarado, Thomas E Witzig, Sandra M Herrmann, Angela Dispenzieri.   

Abstract

BACKGROUND AND OBJECTIVES: Multiple myeloma is responsible for a wide variety of renal pathologies. Urinary protein and monoclonal spike cannot be used to diagnose cast nephropathy (CN). Because albuminuria is a hallmark of glomerular disease, this study evaluated the percentage of urinary albumin excretion (%UAE) as a tool to differentiate CN from Ig light chain amyloidosis (AL), light chain deposition disease (LCDD), and acute tubular necrosis (ATN). DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients were selected from the Renal Biopsy Database and the Dysproteinemia Database. Participants were excluded if laboratory data were missing within 1 week of the renal biopsy. The %UAE was obtained from urine protein electrophoresis.
RESULTS: From 1992 to 2011, 260 patients were biopsied (177 with AL, 28 with LCDD, 43 with CN, and 12 with ATN). The %UAE for CN patients was significantly lower (7%) than for ATN (25%), LCDD (55%), and AL (70%) patients (P<0.001). Significant differences were also found in serum creatinine, serum albumin, free light chain ratio, total urine protein, and urine monoclonal spike; only the %UAE remained independently associated with CN in a logistic regression model (P<0.001). The area under the curve for the receiver operator characteristic curve for %UAE was 0.99. At <25%, the %UAE had a sensitivity of 0.98, specificity of 0.94, positive predictive value of 0.75, and negative predictive value of 0.99.
CONCLUSIONS: This study showed that %UAE was significantly less in CN than the other three renal lesions and %UAE may thus be helpful in diagnosis of CN.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024162      PMCID: PMC3513751          DOI: 10.2215/CJN.11161111

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  31 in total

1.  Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.

Authors:  Alfonso Eirin; Maria V Irazabal; Morie A Gertz; Angela Dispenzieri; Martha Q Lacy; Shaji Kumar; Sanjeev Sethi; Samih H Nasr; Lynn D Cornell; Mary E Fidler; Fernando C Fervenza; Nelson Leung
Journal:  Nephrol Dial Transplant       Date:  2011-11-07       Impact factor: 5.992

2.  Frequency of light chain deposition nephropathy relative to renal amyloidosis and Bence Jones cast nephropathy in a necropsy study of patients with myeloma.

Authors:  B Iványi
Journal:  Arch Pathol Lab Med       Date:  1990-09       Impact factor: 5.534

3.  Controlled plasma exchange trial in acute renal failure due to multiple myeloma.

Authors:  P Zucchelli; S Pasquali; L Cagnoli; G Ferrari
Journal:  Kidney Int       Date:  1988-06       Impact factor: 10.612

4.  Renal failure in multiple myeloma. Pathogenesis and prognostic implications.

Authors:  R Alexanian; B Barlogie; D Dixon
Journal:  Arch Intern Med       Date:  1990-08

5.  Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group.

Authors:  L M Knudsen; M Hjorth; E Hippe
Journal:  Eur J Haematol       Date:  2000-09       Impact factor: 2.997

6.  Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis, and chemotherapy.

Authors:  W J Johnson; R A Kyle; A A Pineda; P C O'Brien; K E Holley
Journal:  Arch Intern Med       Date:  1990-04

7.  Monoclonal gammopathy: significance and possible causality in renal disease.

Authors:  Paisit Paueksakon; Monica P Revelo; Robert G Horn; Scott Shappell; Agnes B Fogo
Journal:  Am J Kidney Dis       Date:  2003-07       Impact factor: 8.860

Review 8.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.

Authors:  Claudio Pozzi; Marco D'Amico; Giovanni B Fogazzi; Simona Curioni; Franco Ferrario; Sonia Pasquali; Giacomo Quattrocchio; Cristiana Rollino; Siro Segagni; Francesco Locatelli
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

9.  Proliferative glomerulonephritis with monoclonal IgG deposits: a distinct entity mimicking immune-complex glomerulonephritis.

Authors:  Samih H Nasr; Glen S Markowitz; M Barry Stokes; Surya V Seshan; Elsa Valderrama; Gerald B Appel; Pierre Aucouturier; Vivette D D'Agati
Journal:  Kidney Int       Date:  2004-01       Impact factor: 10.612

10.  AL-amyloidosis and light-chain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells.

Authors:  John Keeling; Jiamin Teng; Guillermo A Herrera
Journal:  Lab Invest       Date:  2004-10       Impact factor: 5.662

View more
  19 in total

1.  Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study.

Authors:  Heinz Ludwig; Elisabeth Rauch; Thomas Kuehr; Zdeněk Adam; Adalbert Weißmann; Hedwig Kasparu; Eva-Maria Autzinger; Daniel Heintel; Richard Greil; Wolfram Poenisch; Ercan Müldür; Niklas Zojer
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

Review 2.  Myeloma light chain cast nephropathy, a review.

Authors:  Insara Jaffer Sathick; Maria Eleni Drosou; Nelson Leung
Journal:  J Nephrol       Date:  2018-05-05       Impact factor: 3.902

Review 3.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

Review 4.  Diagnostic work-up and specific causes of acute kidney injury.

Authors:  Michael Darmon; Marlies Ostermann; Jorge Cerda; Meletios A Dimopoulos; Lui Forni; Eric Hoste; Matthieu Legrand; Nicolas Lerolle; Eric Rondeau; Antoine Schneider; Bertrand Souweine; Miet Schetz
Journal:  Intensive Care Med       Date:  2017-04-25       Impact factor: 17.440

5.  Successful treatment of myeloma cast nephropathy using bortezomib-based chemotherapy plus selective plasma exchange.

Authors:  Mayuko Kawabe; Izumi Yamamoto; Ai Katsuma; Naomi Hayashi; Yo Komatsuzaki; Yasuyuki Nakada; Akihiro Shimizu; Yudo Tanno; Ichiro Ohkido; Nobuo Tsuboi; Kazuhito Suzuki; Takaki Shimada; Yoji Ogasawara; Katsuki Sugiyama; Keisuke Aiba; Takashi Yokoo
Journal:  CEN Case Rep       Date:  2016-08-11

6.  The light at the end of the tunnel: an unusual case of acute kidney injury in a pediatric patient: Answers.

Authors:  Miriam Steinberg; Joseph P Gaut; Stanley Paul Hmiel; Aadil Kakajiwala
Journal:  Pediatr Nephrol       Date:  2018-03-09       Impact factor: 3.714

Review 7.  Light Chain Cast Nephropathy: Practical Considerations in the Management of Myeloma Kidney-What We Know and What the Future May Hold.

Authors:  Sandhya Manohar; Samih H Nasr; Nelson Leung
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

Review 8.  Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma: a position statement of the Onconephrology Work Group of the Italian Society of Nephrology.

Authors:  P Fabbrini; K Finkel; M Gallieni; G Capasso; M Cavo; A Santoro; S Pasquali
Journal:  J Nephrol       Date:  2016-10-18       Impact factor: 3.902

9.  Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy.

Authors:  Kevin W Finkel; Eric P Cohen; Anushree Shirali; Ala Abudayyeh
Journal:  Clin J Am Soc Nephrol       Date:  2016-08-15       Impact factor: 8.237

10.  A Patient with Abnormal Kidney Function and a Monoclonal Light Chain in the Urine.

Authors:  Nelson Leung; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2016-03-18       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.